These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15314265)

  • 1. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
    Windisch M; Hutter-Paier B; Schreiner E; Wronski R
    J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein: its biological function and role in neurodegenerative diseases.
    Kaplan B; Ratner V; Haas E
    J Mol Neurosci; 2003 Apr; 20(2):83-92. PubMed ID: 12794302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
    Windisch M; Hutter-Paier B; Rockenstein E; Hashimoto M; Mallory M; Masliah E
    J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology.
    Krassnig S; Schweinzer C; Taub N; Havas D; Auer E; Flunkert S; Schreibmayer W; Hutter-Paier B; Windisch M
    Neurodegener Dis; 2015; 15(4):243-57. PubMed ID: 26111745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Wronski R
    Curr Alzheimer Res; 2007 Dec; 4(5):556-61. PubMed ID: 18220522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
    Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
    Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
    Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Hofmeister A; Wronski R
    Curr Alzheimer Res; 2007 Sep; 4(4):446-57. PubMed ID: 17908049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein and transgenic mouse models.
    Fernagut PO; Chesselet MF
    Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein.
    Yang F; Uéda K; Chen P; Ashe KH; Cole GM
    Brain Res; 2000 Jan; 853(2):381-3. PubMed ID: 10640638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein aggregation and neurodegenerative diseases.
    Ma QL; Chan P; Yoshii M; Uéda K
    J Alzheimers Dis; 2003 Apr; 5(2):139-48. PubMed ID: 12719631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.
    Overk CR; Rockenstein E; Florio J; Cheng Q; Masliah E
    Neuroscience; 2015 Dec; 310():549-60. PubMed ID: 26341908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of amyloid-β plaque formation by α-synuclein.
    Bachhuber T; Katzmarski N; McCarter JF; Loreth D; Tahirovic S; Kamp F; Abou-Ajram C; Nuscher B; Serrano-Pozo A; Müller A; Prinz M; Steiner H; Hyman BT; Haass C; Meyer-Luehmann M
    Nat Med; 2015 Jul; 21(7):802-7. PubMed ID: 26099047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.
    Farías GG; Godoy JA; Vázquez MC; Adani R; Meshulam H; Avila J; Amitai G; Inestrosa NC
    Neurobiol Dis; 2005 Feb; 18(1):176-83. PubMed ID: 15649708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
    Windisch M; Wolf H; Hutter-Paier B; Wronski R
    Neurodegener Dis; 2008; 5(3-4):218-21. PubMed ID: 18322395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.